ClinicalTrials.gg
RecruitingNCT06374342Updated Sep 9, 2025

Bone Substitutes Outcomes - Post Market Follow-up

An observational study in Bone Resorption, sponsored by Teknimed. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Teknimed · Observational

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
425
Ages
18 Years and older
Sex
All
01

Study summary

A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Bone Substitute range of products: CERAFORM, TRIHA+, NANOGEL, and all their private labels.

TEKNIMED bone substitutes are legacy products, some marketed for more than 20 years. Their performance and safety have already been demonstrated by Post-Market Surveillance and previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm these claims by collecting data in a "real-life" setting.

The study is a retrospective and prospective global, single arm, non-controlled, multicentric, prospective observational study. Patients will be followed as per local standard medical care of the sites.

Read the detailed description

It is admitted that:

  • Surgeons are often concerned by bone void filling and they can choose between synthetic bone substitutes or bone grafts of animal or human origin.
  • Due to their chemical composition similar to bone tissue, synthetic bone substitutes are an interesting alternative to autografts and allografts which present some inconvenient (quantity to sample, infection of sampling site…).
  • Bone substitutes are bioresorbable and replaced by bone during the healing process (bone remodelling).
  • Nowadays, bone substitutes represent a common and efficient procedure to treat surgical or traumatic osseous defects. They are indicated and used in various pathologies and types of surgery, but they always have the same intended use: to fill a bone void.
  • Bone substitutes are also used in spine surgeries for cage filling and/or posterolateral fusion.

TEKNIMED has developed several bone substitutes currently used in various types of surgery. Due to their increasing use, there is a need of real-life safety and efficacy data on these products.

This retro-prospective study is performed to assess the safety and performance of TEKNIMED bone substitutes in their current clinical use.

02

Conditions studied

  • Bone Resorption

Browse trials for

Keywords

  • Bone substitutes
  • Gel
  • Hydroxyapatite
  • Tricalcium phosphate
  • Calcium phosphate
  • Ceramics
03

In context

Bone Resorption

167 studies on the registry are indexed under Bone Resorption; 28 are open to participants now.

This study's planned enrollment of 425 is above the median of 43 across 18 observational studies indexed under Bone Resorption.

Browse Bone Resorption studies →

Lead sponsor

Teknimed is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People presenting a bone defect created by surgical or traumatic injury.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18 years or older.
  • Be willing to sign an approved by IRB or EC (where applicable) or not being opposed to the use of their clinical data in the study (France) and

    o For prospective inclusion:

  • Be considered for a surgery where bone filling with one of the TEKNIMED bone substitutes comprised in this study is needed and intended to be used according to the IFU.

    o For retrospective inclusion:

  • Have undergone a surgery with a TEKNIMED bone substitute used according to the IFU, between the 1st January 2015 and the date of the site initiation visit
  • Be informed of the study and not being opposed to the use of their clinical data in the study (France) or be willing to sign an informed consent (where applicable) during the first follow-up visit following the site initiation.

Exclusion criteria

Exclusion Criteria:

Patients presenting one of the following conditions will not be included:

  • Under trusteeship or guardianship
  • Pregnancy or breast-feeding women

According to per IFU:

  • Procedures other than those stated in the INDICATIONS section
  • Patients susceptible to allergic reactions to the product components.

CERAFORM®, TRIHA+®:

- Treatment of large bone defects which could impact the stability of bone structure without implementing a mechanical stabilisation system (such as plate(s), screw(s), nail(s), cage(s))

NANOGEL®:

  • Use in vertebroplasty procedures
  • Subcutaneous use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
425 participants (estimated)
Patient registry
No

Groups and cohorts

  • CERAFORM Granules Orthopedics

    Bone grafting

    Device: Bone defect

  • CERAFORM Granules Spine

    Spinal fusion

    Device: Spine fusion

  • CERAFORM Sticks Orthopedics

    Bone grafting

    Device: Bone defect

  • CERAFORM Wedge Orthopedics

    Bone grafting

    Device: Bone defect

  • TRIHA+ Spine

    Spinal fusion

    Device: Spine fusion

  • TRIHA+ Orthopedics

    Bone grafting

    Device: Bone defect

  • NANOGEL Spine

    Cage filling

    Device: Cage filling

  • NANOGEL Orthopedics

    Bone grafting

    Device: Bone defect

Interventions

  • DeviceBone defect

    Bone grafting is a procedure where damaged bones can be repaired or rebuilt using transplanted bone from another source. Sources for transplant bone include the patient (autograft), a cadaver (allograft) or synthetic bone.

  • DeviceSpine fusion

    Spinal fusion is a surgery procedure that reinforces your back structure and stability by linking two vertebrae together

  • DeviceCage filling

    Intervertebral fusion with cages is a surgical procedure used to stabilize the spine by fusing adjacent vertebrae. The cages, typically made of materials like titanium or plastic, and pre-filled with bone graft substitutes are placed between the vertebrae to maintain the proper spacing and alignment.

06

What researchers measure

Primary outcomes

  1. Successful bone repair

    Evaluated through the rate of revision surgery due to a failure of the substitute.

    Time frame: 24 months

Secondary outcomes

  1. Alleviation of Pain

    Pain evaluated by Visual Analogue Scale (VAS): on a scale of 0 to 10, with 0 being no pain and 10 being the most severe pain at the Baseline and at the Follow-up visits

    Time frame: 24 months

  2. Bone reconstruction

    Evaluated on X-Rays by the Lane and Shadu score and the healing stage

    Time frame: 24 months

  3. Well-being

    Evaluated through a series of short questions : On a scale from 0 (Not at all) to 10 (Perfectly well) 1. Are you satisfied with your global health status? \_\_\_\_\_ / 10 2. Do you manage to carry out your day-to-day activities? \_\_\_\_\_ / 10 3. Do you manage to achieve what you would like? \_\_\_\_\_ / 10 4. Do you feel relaxed \_\_\_\_\_ / 10 5. Do you feel fit / with energy? \_\_\_\_\_ / 10 6. Do your physical, psychic and emotional conditions allow you to enjoy your relationships with others? \_\_\_\_\_ / 10

    Time frame: 24 months

  4. Patient satisfaction

    Evaluated through a series of short questions A. Are you satisfied with your surgery? YES/NO/Without opinion B. Has your health improved? YES/STABLE/NO C. Given the results, would you do this intervention again? YES/NO/Without opinion

    Time frame: 24 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06374342
Lead sponsor
Teknimed
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Sep 16, 2021
Primary completion
Sep 16, 2026 (estimated)
Completion
Sep 30, 2032 (estimated)
Last update
Sep 9, 2025

Study contacts

Solange VAN DE MOORTELE, PhD
Contact
s.vandemoortele@teknimed.com
+33534252679

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion